Ann: Paradigm to Present at Evercore ISI HealthCONx Conference, page-175

Sure it does. It shouldn’t be that big of a position in anyone’s portfolio. That’s helpful, sound information if not advice. It should be a hands off equity so you can take advantage of the extreme upside. Micro managing this certain equity will have you out quicker then you should. If you find yourself upset over it, it’s too big of a size for this type of right tail risk position. It just is. Anyone who believes there is significant “de-risk” in a pre-rev biopharm is the one making the error in risk assessment. It’s a $2 usd company for crying out loud. That’s the definition of risk.

its not that they didn’t make a blunder, it just doesn’t matter for what this should be in your portfolio. That is all I am trying to say. There’s a big difference there and, to me, it just reveals some of you are too long as it pertains to your individual portfolio.